Conventional Therapy for Amyloid Light-Chain Amyloidosis

Area of Science:

• Hematology
• Oncology
• Internal Medicine

Background:

• Light-chain (AL) amyloidosis predominantly affects patients ineligible for stem cell transplant.
• Conventional chemotherapy is the primary treatment modality for the majority of AL amyloidosis patients.

Purpose of the Study:

• To review current conventional chemotherapy regimens for AL amyloidosis.
• To discuss risk stratification and the role of specific agents in treatment selection.
• To highlight future directions in combination therapies.

Main Methods:

• Review of current clinical practice and literature on AL amyloidosis chemotherapy.
• Analysis of treatment regimens, including upfront and rescue therapies.
• Discussion of prognostic factors and emerging treatment strategies.

Main Results:

• Conventional regimens combine dexamethasone with alkylating agents (cyclophosphamide, melphalan), proteasome inhibitors (bortezomib, ixazomib), or immunomodulatory drugs (lenalidomide, pomalidomide).
• Treatment selection is guided by organ involvement, comorbidities, and plasma cell clone characteristics.
• Melphalan may be preferred for t(11;14) translocated clones; lenalidomide/pomalidomide are key in rescue settings, though deep responses are infrequent.

Conclusions:

• Conventional chemotherapy remains the cornerstone of AL amyloidosis treatment for most patients.
• Risk stratification is crucial for selecting appropriate chemotherapy combinations.
• Future treatments will likely involve combining chemotherapy with novel agents like immunotherapy to enhance efficacy.